Bibliography
- Miller VA , RielyGJ, ZakowskiMF et al.: Molecular characteristics of bronchioalveolar carcinoma and adenocarcinoma, bronchioalveolar carcinoma subtype, predict response to erlotinib.J. Clin. Oncol.26(9) , 1472–1478 (2008).
- Amado RG , WolfM, PeetersM et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J. Clin. Oncol.26(10) , 1626–1634 (2008).
- Sawyers CL : The cancer biomarker problem.Nature452(7187) , 548–552 (2008).
- Goulart BH , ClarkJW, PienHH et al.: Trends in the use and role of biomarkers in Phase I oncology trials.Clin. Cancer Res.13(22 Pt 1) , 6719–6726 (2007).
- Bodmer W , BonillaC: Common and rare variants in multifactorial susceptibility to common diseases.Nat. Genet.40(6) , 695–701 (2008).
▪ Website
- PharmaGKB: The Pharmacogenetics and Pharmacogenomics Knowledge Base http://pharmgkb.org